Novo Nordisk reports up to 13.8% weight loss in people with obesity receiving semaglutide in phase 2 trial
(Thomson Reuters ONE) -
Bagsværd, Denmark, 23 June 2017 - Novo Nordisk today announced the
headline results from a 52-week double-blind phase 2 clinical trial with once-
daily subcutaneous semaglutide investigating safety and potential for inducing
and maintaining weight loss in people with obesity.
In the trial, 957 people with obesity were randomised to treatment with doses of
semaglutide between 0.05 to 0.4 mg/day or placebo. Liraglutide 3.0 mg/day was
included for comparison. Approximately 100 people were included in each active
treatment arm in combination with diet and exercise. All people in the trial
were treated for 52 weeks followed by a 7-week follow-up period.
From a mean baseline weight of around 111 kg and a body mass index of
approximately 39 kg/m(2), a weight loss up to 17.8 kg was observed after 52
weeks of treatment with semaglutide. This corresponded to an estimated 13.8%
weight loss compared to the weight loss of 2.3% achieved by diet, exercise and
placebo alone, with all treatment arms adjusted for people discontinuing
treatment in the study. The results from the liraglutide 3.0 mg treatment arm
were broadly in line with previously reported data.
Once-daily semaglutide had a well-tolerated safety profile, with the most common
adverse events being gastrointestinal side effects.
"We are very excited about these strong results and the potential of semaglutide
as a new treatment for people with obesity," said Mads Krogsgaard Thomsen,
executive vice president and chief science officer of Novo Nordisk. "We will now
prepare the phase 3 programme with semaglutide to confirm these results. We
expect the phase 3 programme to begin in 2018."
Further information
Media:
Katrine Sperling +45 3079 6718 krsp(at)novonordisk.com
Ken Inchausti (US) +1 609 786 8316 kiau(at)novonordisk.com
Investors:
Peter Hugreffe Ankersen +45 3075 9085 phak(at)novonordisk.com
Hanna Ögren +45 3079 8519 haoe(at)novonordisk.com
Anders Mikkelsen +45 3079 4461 armk(at)novonordisk.com
Kasper Veje (US) +1 609 235 8567 kpvj(at)novonordisk.com
Company announcement No 50 /2017
PR170623_sema_obesity_UK:
http://hugin.info/2013/R/2115373/804945.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 23.06.2017 - 16:45 Uhr
Sprache: Deutsch
News-ID 549579
Anzahl Zeichen: 2929
contact information:
Town:
Bagsvaerd
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 219 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novo Nordisk reports up to 13.8% weight loss in people with obesity receiving semaglutide in phase 2 trial"
steht unter der journalistisch-redaktionellen Verantwortung von
Novo Nordisk A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
